Trial Profile
A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 23 Nov 2020
Price :
$35
*
At a glance
- Drugs Fasinumab (Primary) ; Fasinumab (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 16 Nov 2020 Primary endpoint (Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) Score) has been met.
- 16 Nov 2020 Results published in the Annals of the Rheumatic Diseases.
- 09 Sep 2017 This trial has been completed in Czech Republic.